Loading
Latest filing published 06 Mar 2023 for Concert Pharmaceuticals, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Roger D. Tung, listed as chief executive, appears in our data through filings on Concert Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 7 July 2015 to 6 March 2023, the count stands at 9 filings.
No open-market purchase appears, only 2 sales worth €100k. Other entries cover 1 share grant and 2 option exercises. In 2023 alone, the filings show no purchases and 1 sale.
The newest entry dates from 6 March 2023: a transaction, in Concert Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations